A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

Table 5 Clinical trials of bevacizumab + radiochemotherapy as pre-operative treatment of locally advanced rectal cancer

Author and regimen	No. of patients	pCR (yp T₀-N₀; %)	T-downstaging (%)	Grade 3 most common toxicities
Willet [11]
BVZ + 5FU + RT	32	16^a	50	Diarrhea and hypertension
Spigel [9]
BVZ + 5FU + RT	35	29	NA	Diarrhea
Crane [6]
BVZ + CAP + RT	25	32	64	Perianal desquamation
Velenik [10]
BVZ + CAP + RT	61	13	45	Dermatitis
Kennecke [7]
BVZ + CAP + OX + RT	42	18	NA	Diarrhea
Nogue [8]
BVZ + XELOX → BVZ + CAP + RT	47	36	NA	Rectal tenesmus
Salazar (current study)
BVZ + CAP + RT	44	16	26	Astenia/fatigue
CAP + RT	46	11	18	Astenia/fatigue

Abbreviations: pCR pathological complete response, BVZ bevacizumab, 5FU 5-fluorouracil, CAP capecitabine, OX oxaliplatin, XELOX capecitabine + oxaliplatin, RT radiotherapy, NA not available.
^aypT_0.

ISSN: 1471-2407